Dr Josep Tabernero MD PhD is Head of the Medical Oncology Department at Vall d’Hebron University Hospital and Director of the Vall d’Hebron Institute of Oncology in Barcelona (Spain) and Professor of Medicine at the Universitat de Vic/UCC.
He has been Principal Investigator of several Phase I pharmacodynamic studies with tumour-directed targeted therapies and immune-based therapies. His research has been focused on the development of molecular targeted therapies and the identification of molecular biomarkers of response/ resistance, and it is formed by both clinical and translational researchers, working in various thematic areas (sophisticated preclinical models, liquid biopsies, microbiome).
Dr Tabernero serves on the Editorial Boards of various top tier journals including Cancer Discovery, Cancer Treatment Reviews, and Nature Reviews Clinical Oncology. He has (co) authored approximately 600 peer-reviewed papers with an H-Index of 122. He was the President (2018 – 2019) of the European Society for Medical Oncology´s (ESMO). He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO). He has also been a member of the Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, TAT and ESMO-GI meetings.